Table 1.
Clinical stage T-cell receptor (Target x CD3) T-cell engagers.
| Class of target | Name | Target | Design | Status | NCT or EudraCT | Sponsor |
|---|---|---|---|---|---|---|
| Lineage antigens | Tebentafusp (IMC-gp100) | gp100 | Full-length alpha and beta chains Stcr | OS benefit in metastatic uveal melanoma (8). Approved for metastatic and unresectable uveal melanoma | NCT03070392 | Immunocore |
| RG6007 | WT1 | TCR mimetic antibody | Phase 1 (multiple tumors) | NCT04580121 | Roche | |
| IMC-C103C | MAGE-A4 | Full-length alpha and beta chains sTCR | Clinical activity in ovarian and HNSCC cancer. Phase 1 (multiple tumors; ref. 55) | NCT03973333 | Immunocore and Genentech | |
| IMC-F106C | PRAME | Full-length alpha and beta chains sTCR | Phase 1 (multiple tumors) | NCT04262466 | Immunocore | |
| Cancer–testes antigens | RG8129 | MAGE-A4 | TCR mimetic antibody | Phase 1 (multiple tumors) | NCT01694472 | Roche |
| IMA401 | MAGE-A4 | Single chain of alpha and beta variable chain sTCR | Phase 1 (multiple tumors) | NCT05359445 | Immatics and Bristol-Myers Squibb | |
| IMC-NYESO | NYESO | Full-length alpha and beta chains sTCR | Discontinued | NCT03515551 | Immunocore and GSK | |
| Viral antigens | IMV | HBV | Full-length alpha and beta chains sTCR | Phase 1 (chronic HBV) | 2019–004212–64 | Immunocore |
| Differentially expressed | ABBV-184 | Survivin | Single chain of alpha and beta variable chain sTCR | Discontinued | NCT04272203 | AbbVie |